花園生物(300401.SZ):金西科技園3個項目投產
格隆匯11月11日丨花園生物(300401.SZ)公佈,收購金西科技園部分項目經過前期調試、試運行,相關生產線於近日投產。
根據杭州市產業結構調整的需要,公司全資子公司下沙生物、洛神科技決定搬遷至金華經濟技術開發區;同時,為了集中生產管理、提高資金使用效率、實現資源整合、降低運營成本,公司的生產基地將逐步遷移至金華經濟技術開發區。為此,公司在金華經濟技術開發區設立了全資子公司花園營養,花園營養購買了771畝土地用於金西科技園項目的建設。
金西科技園項目統一規劃,分步建設,目前金西科技園在建項目包括2017年非公開發行募投項目、2019年非公開發行募投項目及自籌資金建設項目。
金西科技園近日投產的部分項目為2017年非公開發行募投項目“年產180噸7-去氫膽固醇項目”、“年產750噸飼料級VD3油劑項目”及自籌資金建設項目“年產18噸膽鈣化醇項目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.